<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01315132</url>
  </required_header>
  <id_info>
    <org_study_id>08D.85</org_study_id>
    <secondary_id>2007-61</secondary_id>
    <nct_id>NCT01315132</nct_id>
  </id_info>
  <brief_title>A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies</brief_title>
  <official_title>A Two Step Approach To Matched-Sibling Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study uses a drug called cyclophosphamide to decrease the incidence of GVHD in
      matched sibling hematopoietic stem cell transplant. In doing so, the goal of the study is to
      increase overall survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research protocol has been developed for patients undergoing matched-sibling
      hematopoietic stem cell transplant (HSCT). The patients who are treated according to this 2
      step allogeneic HSCT protocol will receive cyclophosphamide to induce in-vivo tolerization of
      both autologous and allogeneic lymphocytes, followed by an allogeneic CD34-selected HSCT. The
      primary research questions relate to immune reconstitution, incidence of GVHD, and relapse in
      patients who receive lymphocyte treatment of this type in allogeneic HSCT and how it impacts
      overall survival.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 10, 2008</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 Year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Engraftment, immune reconstitution, GVHD</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Hematological Malignancies</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Hodgkin's Disease</condition>
  <arm_group>
    <arm_group_label>Allogeneic Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matched Sibling Allogeneic Transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Matched Sibling Allogeneic Transplantation</intervention_name>
    <description>Patients undergoing myeloablative hematopoietic stem cell transplant from HLA identical related donors using cyclophosphamide tolerization</description>
    <arm_group_label>Allogeneic Transplantation</arm_group_label>
    <other_name>CliniMACS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Any patient with a hematologic or oncologic diagnosis in which allogeneic HSCT is
             thought to be beneficial, and in whom front-line therapy has already been applied.
             Patients will be considered high-risk if they have any of the following:

               1. Age &gt; 50 years

               2. ECOG Performance status of &lt;2

               3. Acute leukemia: requiring more than one chemotherapy regimen to obtain 1st CR;
                  second or greater CR, 1st relapse; any ph+ ALL

               4. CML 2nd chronic phase, accelerated phase, or blastic phase

               5. MDS with IPS of Intermediate 2 or greater

               6. Any myeloproliferative disorder

               7. Hodgkin lymphoma: relapsed, refractory, or primary induction failure

               8. Non-Hodgkin lymphoma: relapsed, refractory, primary treatment failure, or not
                  eligible for an autologous HSCT

               9. Other conditions not listed will be assessed as high-risk by the PI

          2. Patients must have a related donor who is either HLA-identical or a one antigen
             mismatch at the HLA- A; B; C; and DR loci.

          3. Patients must adequate organ function:

               1. LVEF of &gt;45%

               2. DLCO (adjusted for hemoglobin) &gt;45% of predicted

               3. Adequate liver function as defined by a serum bilirubin &lt;1.8, AST or ALT &lt; 2.5X
                  upper limit of normal

               4. Creatinine clearance of &gt; 60 ml/min

          4. Patients must be willing to use contraception if they have childbearing potential

          5. Able to give informed consent

        Exclusion Criteria:

          1. ECOG performance status of 3 or 4.

          2. HIV positive

          3. Active involvement of the central nervous system with malignancy

          4. Psychiatric disorder that would preclude patients from signing an informed consent

          5. Pregnancy

          6. Patients with life expectancy of &lt; 6 months for reasons other than their underlying
             hematologic/oncologic disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neal Flomenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Neal Flomenberg, MD</last_name>
    <phone>215-955-4367</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neal Flomenberg, MD</last_name>
      <phone>215-955-4367</phone>
    </contact>
    <investigator>
      <last_name>Neal Flomenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dolores Grosso, DNP, CRNP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John L Wagner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joanne Filicko-O'Hara, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Carabasi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margaret Kasner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William O'Hara, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Werner-Wasik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>S. Onder Alpdogan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wenyin Shi, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Weiss, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Beth Colombe, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ubaldo Martinez Outschoorn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.KimmelCancerCenter.org</url>
    <description>Kimmel Cancer Center at Thomas Jefferson University, an NCI-Designated Cancer Center</description>
  </link>
  <link>
    <url>http://www.JeffersonHospital.org</url>
    <description>Thomas Jefferson University Hospitals</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2011</study_first_submitted>
  <study_first_submitted_qc>March 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2011</study_first_posted>
  <last_update_submitted>November 8, 2017</last_update_submitted>
  <last_update_submitted_qc>November 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myeloablative Hematopoietic Stem Cell Transplant</keyword>
  <keyword>Cyclophosphamide tolerization</keyword>
  <keyword>2 Step Approach</keyword>
  <keyword>Hematological malignancies</keyword>
  <keyword>leukemia</keyword>
  <keyword>lymphoma</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>Hodgkin's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

